Tchaikapharma High Quality Medicines Inc. Statement of financial position as of 31 December 2020

ASSETS	31.12.2020	31.12.2019
Non-current assets	BGN'000	BGN'000
Property, plant and equipment	37 123	26 981
The property of the property o	3 8 1 6	2 725
Intangible assets		
Assets with right to use Investments in subsidiaries	210	420
	19	4.020
Trade receivables	5 157	4 930
Total non-current assets	46 325	35 056
Current assets	10.042	0.762
Inventories To describe the second of the se	10 842	8 763
Trade and other receivables	60 084	74 020
Current corporation tax	14	,
Treasury shares redeemed	1	1
Cash and cash equivalents	45	40
Total current assets	70 986	82 824
Total assets	117 311	117 880
LIABILITIES		
Equity		
Share capital	82 200	82 200
Reserves	12 032	11 775
Retained earnings	2 904	2 568
Total	97 136	96 543
Non-current liabilities		
Long-term loans	1 731	2 037
Deferred tax liabilities	1 139	1 308
Retirement benefit obligations	194	159
Total non-current liabilities	3 064	3 504
Current liabilities		
Trade and other liabilities	6 583	7 095
Short-term loans	9 783	9 784
Current portion of long-term loans	541	616
Current corporate income tax		142
Other tax liabilities	204	196
Total current liabilities	17 111	17 833
Total liabilities	20 175	21 337
Total equity and liabilities	117 311/	117 880
Date of preparation: 26.03.2021		TUN

Date of preparation: 26.03.2021

Sofia Prepared by:..

B. Georgiey/

Tchaikapharma High Quality Medicines Inc. Statement of comprehensive income for the year ended 31 December 2020

	31.12.2020	31.12.2019
	BGN'000	BGN'000
Revenue	40 105	34 443
Other income	283	281
Total income	40 388	34 724
Carrying amount of goods sold Changes in inventories of finished products and	(817)	(748)
work in progress	(784)	1 734
Materials and services	(28 405)	(24 708)
Personnel expenses	(4 960)	(4 359)
Depreciation / amortisation expenses	(4 231)	(3 526)
Depreciation costs	(50)	(4)
Other expenses	(602)	(799)
Finance income	521	385
Finance costs	(436)	(366)
Total expenses	(39 764)	(31 761)
Profit before taxation	624	2 963
Corporate income tax expense	(20)	(395)
Profit/Loss for the period Gain/(Loss) on revaluation of the fair value of land and buildings Changes due to deformed tay for land and	604	2 568
Changes due to deferred tax for land and buildings	(7)	(7)
Revaluation of defined benefit pension funds	(4)	(20)
Changes due to deferred tax for pension funds	(.)	2
Other comprehensive income for the period		(25)
Total comprehensive income for the period	593	2 543
Earnings per share / in BGN per 1 share /	0.007	0.03

Date of preparation: 26.03.2021

Sofia

Prepared by:..

P. Moneva /

Executive Director.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc. Cash flow statement for the year ended 31 December 2020

	31.12.2020 BGN'000	31.12.2019 BGN'000
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	35 208	30 470
Payments to suppliers of materials, goods and services	(22940)	(17623)
Payments to personnel	(4 802)	(4249)
Payments of interest and dividends	(19)	(32)
Corporate income tax payments	(352)	(339)
Other proceeds / payments	(3 609)	(6 003)
Net cash flows	3 486	2 224
Cook flows from investing a strict		
Cash flows from investing activities	(0.00	44 - A
Payments on non-current assets acquired	(2 907)	(1 170)
Other investing activities	(19)	
Net cash flows	(2 926)	(1 170)
Cash flows from financial activities		
Proceeds from loans	200	217
Payments on loans	(201)	(215)
Payment of interest, dividends	(196)	(197)
Payments on finance lease	(358)	(1 073)
Other proceeds/payments		4
Net cash flows	(555)	(1 264)
Change in cash and cash equivalents	5	(210)
Cash and cash equivalents at the beginning of the period	40	250
Cash and cash equivalents at the end of the period	45	40

P. Moneva /

Date of preparation: 26.03.2021

Sofia Prepared by:..

/B. Georgiev /

Executive

Director:.....

Tchaikapharma High Quality Medicines Inc. Statement on changes in equity for the year ended 31 December 2020

Regint Regint Reserves Reserves Reserves Regint Regi		Registered (share)	Revaluation	Other	Retained	Total
Profit/loss for the period C25 C25 C25 C25 Including from tax effect of the revaluation of property, plant and equipment		capital	reserves			
Profit/loss for the period 2 568 2 568 2 568 C(25)	B. I					
Comprehensive income	Contraction of the Contraction o	72 200	4 124	6 477		
Including from tax effect of the revaluation of property, plant and equipment	•				2 568	
Total comprehensive income (25) 2 568 2 543	Other comprehensive income		(25)			(25)
Dividends accrued	revaluation of property, plant and					
Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period Balance as of 31.12.2019 Balance as of 01.01.2020 Balance as of 01.01.2020 Profit/loss for the period Other comprehensive income (11) Total comprehensive income (12) Total comprehensive income (13) Total comprehensive income (14) Total comprehensive income (15) Total comprehensive income (16) Tot	Total comprehensive income		(25)		2 568	2 543
Profit transferred to reserves	Dividends accrued	10 000			(10 000)	
Sexpenses recognised during the period 10 000 1 199 (1 199)	Profit transferred to reserves			1 199	(1 199)	
Balance as of 31.12.2019 82 200 4 099 7 676 2 568 96 543 Balance as of 01.01.2020 82 200 4 099 7 676 2 568 96 543 Profit/loss for the period Other comprehensive income (11) 604 604 Total comprehensive income (11) 604 593 Issue of shares by the owners Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period 268 (268)	expenses recognised during the	10 000		1 199	(1 199)	
Profit/loss for the period 604 604 Other comprehensive income (11) (11) Total comprehensive income (11) 604 593 Issue of shares by the owners Dividends accrued Tantiemmes accrued Profit transferred to reserves 268 (268) Total amount of income and expenses recognised during the period 268 (268)	Balance as of 31.12.2019		4 099			96 543
Other comprehensive income (11) Total comprehensive income (11) (11) 604 593 Issue of shares by the owners Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period Description of 20110 2000 268 (268)		82 200	4 099	7 676	2 568	96 543
Total comprehensive income (11) Issue of shares by the owners Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period Polymer (21) 12 2000 (11) (11) (17) (17) (18) (28) (268)					604	
Issue of shares by the owners Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period 268 (268)	Secretary and the secretary secretar					100000-10
Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period 268 (268)	Total comprehensive income		(11)		604	593
Dividends accrued Tantiemmes accrued Profit transferred to reserves Total amount of income and expenses recognised during the period 268 (268)	Issue of shares by the owners					
Profit transferred to reserves Total amount of income and expenses recognised during the period 268 (268) 268 (268)	CHIPPERSON CONTRACTOR					
Total amount of income and expenses recognised during the period 268 (268)	Tantiemmes accrued					
200 (200)	Total amount of income and expenses recognised during the			268	(268)	
Balance as of 31.12.2020 82 200 4 088 7 944 2 904 97 136	• · · · · · · · · · · · · · · · · · · ·			268	(268)	
	Balance as of 31.12.2020	82 200	4 088	7 944	2 904	97 136

Date of preparation: 26.03.2021

Sofia

Prepared by:....

JP. Moneva/

Executive Director:....

/B. Georgiev /